{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.33","upperLimit":"12.62","value":"9.23"},{"groupId":"OG001","lowerLimit":"5.13","upperLimit":"7.33","value":"6.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method. Hazard ratio (HR) and the corresponding Confidence Interval (CI) were estimated in a stratified Cox proportional hazards model for distribution of OS in each randomized arm. Survival follow-up analysis occurred at the end of the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From the date of first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first, up to approximately 103 months","title":"Overall Survival (OS) Time in Months for All Randomized Participants - Extended Collection","type":"POST_HOC","unitOfMeasure":"Months"}